Skip to content
Research Article Open access CC BY 4.0

Artificial Intelligence in Toxicology and Pharmacology

Siddhesh Nasnodkar, Burak Cinar, Stephanie Ness

Journal of Engineering Research and Reports · pp. 192–206 · Published 24 Aug 2023

10.9734/jerr/2023/v25i7952

Abstract

Methods that utilize machine learning and artificial intelligence have transformed a wide variety of fields, including the field of toxicology. Physiologically based pharmacokinetic (PBPK) modeling, quantitative structure-activity relationship modeling for toxicity prediction, adverse outcome pathway analysis, high-throughput screening, toxicogenomics, big data, and toxicological databases are just some of the areas that are covered in this review. By leveraging machine learning and artificial intelligence approaches, it is now possible to develop PBPK models for hundreds of chemicals in an efficient manner, to create in silico models to predict toxicity for a large number of chemicals with similar accuracies compared with In vivo animal experiments, and to analyze a large amount of data of various types (toxicogenomics, high-content image data, etc.) to generate new insights into toxicity mechanisms rapidly, which was previously impossible. This is an improvement over the previous situation The field of toxicological sciences faces a number of challenges that must be overcome before it can make further progress. These challenges include the following: (1) not all machine learning models are equally useful for a particular type of toxicology data; therefore, it is important to test different methods to determine the optimal approach; (2) the current toxicity prediction is primarily based on bioactivity classification (yes/no); therefore, additional studies are required to predict the intensity of effect or dose-response relationship.

Artificial intelligence pharmacology toxicology machine learning

References (85)

  1. 1 Convolutional neural networks: an overview and application in radiology [DOI]
  2. 2 ChEMBL: towards direct deposition of bioassay data [DOI]
  3. 3 Robust Physical-World Attacks on Deep Learning Visual Classification [DOI]
  4. 4 Inverse molecular design using machine learning: Generative models for matter engineering [DOI]
  5. 5 Planning chemical syntheses with deep neural networks and symbolic AI [DOI]
  6. 6 The rise of deep learning in drug discovery [DOI]
  7. 7 Molecular graph convolutions: moving beyond fingerprints [DOI]
  8. 8 Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks [DOI]
  9. 9 Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17 [DOI]
  10. 10 Molecular de-novo design through deep reinforcement learning [DOI]
  11. 11 Deep Neural Nets as a Method for Quantitative Structure–Activity Relationships [DOI]
  12. 12 A Mathematical Contribution to Structure-Activity Studies [DOI]
  13. 13 Automating drug discovery [DOI]
  14. 14 Hidden technical debt in Machine learning systems
  15. 15 Low Data Drug Discovery with One-Shot Learning [DOI]
  16. 16 Machine Learning in Computer-Aided Synthesis Planning [DOI]
  17. 17 The Chemical Space Project [DOI]
  18. 18 A graph-convolutional neural network model for the prediction of chemical reactivity [DOI]
  19. 19 Artificial intelligence, machine learning and health systems [DOI]
  20. 20 DNA-encoded chemistry: enabling the deeper sampling of chemical space [DOI]
  21. 21 Large-scale comparison of machine learning methods for drug target prediction on ChEMBL [DOI]
  22. 22 How not to develop a quantitative structure–activity or structure–property relationship (QSAR/QSPR) [DOI]
  23. 23 Artificial intelligence in medicine: current trends and future possibilities [DOI]
  24. 24 Similarity to Molecules in the Training Set Is a Good Discriminator for Prediction Accuracy in QSAR [DOI]
  25. 25 ImageNet: Constructing a large-scale image database [DOI]
  26. 26 Is Multitask Deep Learning Practical for Pharma? [DOI]
  27. 27 Active-learning strategies in computer-assisted drug discovery [DOI]
  28. 28 Deep Learning Based Regression and Multiclass Models for Acute Oral Toxicity Prediction with Automatic Chemical Feature Extraction [DOI]
  29. 29 The next level in chemical space navigation: going far beyond enumerable compound libraries [DOI]
  30. 30 ADME Properties Evaluation in Drug Discovery: Prediction of Caco-2 Cell Permeability Using a Combination of NSGA-II and Boosting [DOI]
  31. 31 Advancing Computational Toxicology in the Big Data Era by Artificial Intelligence: Data-Driven and Mechanism-Driven Modeling for Chemical Toxicity [DOI]
  32. 32 New drugs cost US$2.6 billion to develop [DOI]
  33. 33 Computational prediction of chemical reactions: current status and outlook [DOI]
  34. 34 Interpretation of QSAR Models by Coloring Atoms According to Changes in Predicted Activity: How Robust Is It? [DOI]
  35. 35 Data integration: challenges for drug discovery [DOI]
  36. 36 Cybernetics and forecasting techniques
  37. 37 Multi-objective active machine learning rapidly improves structure–activity models and reveals new protein–protein interaction inhibitors [DOI]
  38. 38 Imputation of Assay Bioactivity Data Using Deep Learning [DOI]
  39. 39 The advancement of multidimensional QSAR for novel drug discovery - where are we headed? [DOI]
  40. 40 Clinical Toxicology: Principles and Mechanisms
  41. 41 Environmental Chemical Assessment in Clinical Practice: Unveiling the Elephant in the Room [DOI]
  42. 42 Estimation of the applicability domain of kernel-based machine learning models for virtual screening [DOI]
  43. 43 Virtual Screening Using Binary Kernel Discrimination: Analysis of Pesticide Data [DOI]
  44. 44 Quantitative structure/property relationship analysis of Caco‐2 permeability using a genetic algorithm‐based partial least squares method [DOI]
  45. 45 ChemInform Abstract: Validation of Reaction Vectors for de novo Design [DOI]
  46. 46 Junction Tree Variational Autoencoder for Molecular Graph Generation [DOI]
  47. 47 Extraction of chemical structures and reactions from the literature [DOI]
  48. 48 Optimizing distributions over molecular space. An Objective-Reinforced Generative Adversarial Network for Inverse-design Chemistry (ORGANIC) [DOI]
  49. 49 The Secret Sharer: Measuring Unintended Neural Network Memorization & Extracting Secrets
  50. 50 Adversarial Controls for Scientific Machine Learning [DOI]
  51. 51 Applications of machine learning in drug discovery and development [DOI]
  52. 52 Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules. [DOI]
  53. 53 Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery [DOI]
  54. 54 Accurate De Novo Prediction of Protein Contact Map by Ultra-Deep Learning Model [DOI]
  55. 55 Rethinking drug design in the artificial intelligence era [DOI]
  56. 56 Deep learning for molecular design—a review of the state of the art [DOI]
  57. 57 Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions [DOI]
  58. 58 A de novo molecular generation method using latent vector based generative adversarial network [DOI]
  59. 59 Artificial Intelligence for Drug Toxicity and Safety [DOI]
  60. 60 Why deep-learning AIs are so easy to fool [DOI]
  61. 61 Synthetic organic chemistry driven by artificial intelligence [DOI]
  62. 62 A Deep Learning Approach to Antibiotic Discovery [DOI]
  63. 63 Assessing the impact of generative AI on medicinal chemistry [DOI]
  64. 64 Predicting drug-target interaction network using deep learning model [DOI]
  65. 65 Biosystems Design by Machine Learning [DOI]
  66. 66 Modeling Physico-Chemical ADMET Endpoints with Multitask Graph Convolutional Networks [DOI]
  67. 67 Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery [DOI]
  68. 68 Validating the validation: reanalyzing a large-scale comparison of deep learning and machine learning models for bioactivity prediction [DOI]
  69. 69 BRADSHAW: a system for automated molecular design [DOI]
  70. 70 Perspective on model‐informed drug development [DOI]
  71. 71 An Introduction to Interdisciplinary Toxicology [DOI]
  72. 72 Evaluation of data augmentation via synthetic images for improved breast mass detection on mammograms using deep learning [DOI]
  73. 73 Role of Disease Progression Models in Drug Development [DOI]
  74. 74 A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning-integrated modeling platform [DOI]
  75. 75 Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform [DOI]
  76. 76 The Role and Promise of Artificial Intelligence in Medical Toxicology [DOI]
  77. 77 Enhancing reaction-based de novo design using a multi-label reaction class recommender [DOI]
  78. 78 Model‐Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients [DOI]
  79. 79 In Silico Simulation of the Systemic Drug Exposure Following the Topical Application of Opioid Analgesics in Patients with Cutaneous Lesions [DOI]
  80. 80 Introduction to clinical toxicology [DOI]
  81. 81 Clinical toxicology and clinical analytical toxicology [DOI]
  82. 82 A Graph-Convolutional Neural Network Model for the Prediction of Chemical Reactivity [DOI]
  83. 83 Modeling Physico-Chemical ADMET Endpoints With Multitask Graph Convolutional Networks [DOI]
  84. 84 AI developers tout revolution, drugmakers talk evolution [DOI]
  85. 85 De Novo Generation of Hit-like Molecules from Gene Expression Signatures Using Artificial Intelligence [DOI]

Cited by 45

The recent advances in the approach of artificial intelligence (AI) towards drug discovery

Mahroza Kanwal Khan, Mohsin Raza, Muhammad Shahbaz · Frontiers in Chemistry · 2024

Ensuring human oversight in high-performance AI systems: A framework for control and accountability"

Joel Frenette · World Journal of Advanced Research and Reviews · 2023

Using Graph Neural Networks in Network Pharmacology for Predicting Drug Disease Associations

Khushboo Jain, Richa K. Makhijani, Ruchira Selote · Procedia Computer Science · 2026

The Role of AI in Cyber Security: Safeguarding Digital Identity

Mohammad Hassan Yousif Binhammad, Shaikha Alqaydi, Azzam Othman · Journal of Information Security · 2024

Business Practices in the Age of AI

Shalini Kumari Maurya, Jaspreet Kaur · Advances in Medical Technologies and Clinical Practice · 2024

AI-designed drugs: clinical development and future directions

Raja Ahmed, Suraiya Akhtar, Ankur Das · Revolutionizing Drug Development · 2026

Showing 16 of 45 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

46

Page views

0

PDF downloads

4

Outbound clicks

45

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.